ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 55 filers reported holding ARBUTUS BIOPHARMA CORP in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $47,116 | +48.4% | 15,248 | +23.9% | 0.00% | – |
Q1 2024 | $31,755 | +3.2% | 12,308 | 0.0% | 0.00% | – |
Q4 2023 | $30,771 | +23.2% | 12,308 | 0.0% | 0.00% | – |
Q3 2023 | $24,985 | -22.7% | 12,308 | -12.4% | 0.00% | – |
Q2 2023 | $32,332 | -12.5% | 14,057 | +15.2% | 0.00% | – |
Q1 2023 | $36,960 | +30.0% | 12,198 | 0.0% | 0.00% | – |
Q4 2022 | $28,421 | +23.6% | 12,198 | 0.0% | 0.00% | – |
Q3 2022 | $23,000 | -17.9% | 12,198 | +16.5% | 0.00% | – |
Q2 2022 | $28,000 | +16.7% | 10,466 | +31.6% | 0.00% | – |
Q1 2022 | $24,000 | -4.0% | 7,951 | +21.9% | 0.00% | – |
Q4 2021 | $25,000 | -10.7% | 6,525 | 0.0% | 0.00% | – |
Q3 2021 | $28,000 | +47.4% | 6,525 | +4.6% | 0.00% | – |
Q2 2021 | $19,000 | +72.7% | 6,241 | +18.9% | 0.00% | – |
Q2 2019 | $11,000 | -42.1% | 5,247 | 0.0% | 0.00% | – |
Q1 2019 | $19,000 | -82.6% | 5,247 | -81.5% | 0.00% | – |
Q4 2018 | $109,000 | -53.0% | 28,407 | +15.8% | 0.00% | – |
Q3 2018 | $232,000 | +510.5% | 24,540 | +367.7% | 0.00% | – |
Q2 2018 | $38,000 | – | 5,247 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
QVT Financial LP | 16,013,540 | $39,233,000 | 1.19% |
ARMISTICE CAPITAL, LLC | 1,940,000 | $4,753,000 | 1.12% |
DAFNA Capital Management LLC | 234,000 | $573,000 | 0.50% |
Alpha Wave Global, LP | 1,655,162 | $4,055,000 | 0.43% |
Telemetry Investments, L.L.C. | 150,000 | $368,000 | 0.21% |
LADENBURG THALMANN FINANCIAL SERVICES INC. | 5,294,945 | $12,972,000 | 0.18% |
SABBY MANAGEMENT, LLC | 792,617 | $1,942,000 | 0.11% |
K2 PRINCIPAL FUND, L.P. | 443,887 | $1,088,000 | 0.10% |
Anson Funds Management LP | 105,085 | $257,000 | 0.08% |
DIALECTIC CAPITAL MANAGEMENT, LP | 25,000 | $61,000 | 0.03% |